Obstipation in the elderly
Authors:
M. Berková; Z. Berka; E. Topinková
Published in the journal:
Geriatrie a Gerontologie 2016, 5, č. 4: 209-216
Category:
Review Article
Summary
Constipation affects up to 30% of the elderly population in the developed world. It can be a transient, benign condition, but it can also be a symptom of a serious disease. According to its duration, we classify constipation into chronic and acute, according to aetiology we classify it into primary and secondary. Constipation can be functional or organic. Chronic functional constipation is defined by the Rome criteria III (ROMA III). According to the type of the intestinal dysfunction, we differentiate among chronic functional obstipation: a) with normal passage, b) slowed passage, c) incomplete evacuation and d) combined symptoms. In seniors we commonly encounter chronic functional constipation lasting many years, which is made worse by lack of exercise, insufficient fibre and fluid intake, medication related issues and age-induced changes in the bowel and its innervation. It is important to rule out a serious organic disease, especially a malignancy, when presented with a new case of a senior with constipation issues. A rare complication of stool impaction is a stercoidal ulcer causing intestinal haemorrhage or perforation, especially in bedridden patients, immunocompromised patients and patients with ischemised large intestine wall. Three groups of laxatives are used to treat functional obstipation: volume, osmotic and contact. If their effects are insufficient, it is possible to try the prokinetic prucaloprid. Newer entries in the laxative category include chloride canal activators and guanylate cyclase receptor activators. In disorders with incomplete bowel evacuation, it is best to train the patient in a synergic response of the pelvic floor, assuming the patient is capable of cooperation. It is however true that in many polymorbid seniors with cognitive deficits, this method is not suitable.
KEYWORDS:
Constipation – obstipation – criteria Roma III - laxatives
Zdroje
1. Basilisco G, Coletta M. Chronic constipation. A critical review. Dig Liver Dis 2013; 45(11): 886–93.
2. Bharucha A, Pemberton J, Locke G. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144(1): 218–38.
3. Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic constipation in the elderly. Am J Gastroenterol 2012; 107: 18–25.
4. McCrea G, Miaskowski C, Stotts N, et al. A review of the literature on gender and age differences in the prevalence and characteristics of constipation in North America. J Pain Symptom Manag 2009; 37(4): 737–45.
5. Mugie S, Benninga M, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol 2011; 25(1): 3–18.
6. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011; 25(Suppl B): 11B–5B.
7. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging (Milano) 1991; 3: 161–170.
8. Lüllmann-Rauch R. Histologie. Praha: Grada Publishing 2012; 320–378.
9. Suares N, Ford A. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and metaanalysis. Am J Gastroenterol 2011; 106(9): 1582–91.
10. Andromanakos NP, Pinis SI, Kostakis Al. Chronic severe constipation: current pathophysiological aspects, new diagnostic approaches, and therapeutic options. Eur J Gastroenterol Hepatol 2015; 27(3): 204–214.
11. Wedel T, Spiegler J, Soellner S, et al. Enteric nerves and interstitial cells of Cajal are altered in patients with slow-transit constipation and megacolon. Gastroenterology 2002; 123(5): 1459–1467.
12. Vierhout ME, Schreuder HW, Veen HF. Severe slow-transit constipation following radical hysterectomy. Gynecol Oncol 1993; 51: 401–403.
13. Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation – a European perspective. Neurogastroenterol Motil 2011; 23(8): 697–710.
14. Bharucha AE, Wald A, Enck P, et al. Functional anorectal disorders. Gastroenterology 2006; 130(5): 1510–1518.
15. Sbahi H, Cash BD. Chronic Constipation: a review of current literature. Curr Gastroenterol Rep 2015; 17: 47.
16. Camilleri M, Lee JS, Viramontes B, et al. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome and diverticulosis in older people. J Am Geriatr Soc 2000; 48: 1142–1450.
17. Lukáš M. Syndrom dráždivého tračníku. Interní Med 2007; 9(12): 544–547.
18. Chiarioni G,Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130: 657–664.
19. Rao S, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedbac, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007; 5(3): 331–338.
20. Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007; 50(4): 428–441.
21. Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25(5): 599–608.
22. Müller-Lissner S, Tack J, Feng Y, et al. Levels of satisfaction withcurrent chronic constipation treatment options in Europe – an internet survey. Aliment Pharmacol Ther 2012; 37(1): 137–45.
23. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170–177.
24. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138: 886–895.
25. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527–536.
26. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs 2010; 19: 765–775 .
27. Al-Huniti N, Nielsen JC, Hutmacher MM, Lappalainen J, Cantagallo K, Sostek M. Population exposure-response modeling of naloxegol in patients with noncancer-related pain and opioid-induced constipation. CPT Pharmacometrics Syst Pharmacol 2016; 5(7): 359–366
28. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009; 7(1): 39-46.
29. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexonetreatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009; 38(5): 683–690.
30. Bruner HC, Atayee RS, Edmonds KP, Buckholz GT. Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res 2015; 8: 289–294
31. Madan P, Bhayana S, Chandra P, Hughes JI. Lower gastrointestinal bleeding: Association with Sevelamer use. World J Gastroenterol 2008; 14(16): 2615–2616.
32. Huang CC, Wang IF, Chiu HH. Lower gastrointestinal bleeding caused by stercoral ulcer. CMAJ 2011; 183(2): 134.
Štítky
Geriatrics General practitioner for adults Orthopaedic prostheticsČlánok vyšiel v časopise
Geriatrics and Gerontology
2016 Číslo 4
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- Obstipation in the elderly
- Diabetes and dementia – what is known about their relationship?
- Acute and late onset complications of diabetes – do they pose a significant problem in the elderly?
- A cutaneous lymphomatic disease at geriatric patient